Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OphtiMed
Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
OphtiMedRx is developing OM-301, a first-in-class anti-senescence small molecule therapy targeting retinal pigment epithelial cell senescence for dry AMD, showing robust in vivo/in vitro preclinical proof-of-concept and aiming for IND and first-in-human trials in late 2025[1][2][3][4].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Israel Innovation Authority (IIA)Women TechEUGO Innovation GroupGalil Ofek VenturesMor Research ApplicationsRunYoung organization[1][2][5]
Beyond the preview
Go deeper on OphtiMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OphtiMed.